Exactly. The current share price assumes Q1 will be a total bomb...i.e. maybe 5000 or 6000 cases sold and revenues similar to 2016 total ($300,000-350,000).
Even if the revenues disappoint...maybe $700,000-$800,000, this will represent a delay of a quarter or so in execution of the company's business plan. Similar to what happened to Phase II, it was delayed in execution about a quarter.
These delays of a quarter or so will have little or no impact for those of us who are longs IMO. I'm in 'till end of 2018 or the buyout.